Innovation Norway Grant Funding

By Ubbat Ocak in 2021 Posted March 6, 2021

MUB Medical Secures Funding from Innovation Norway to Advance Innovation and Development Efforts

MUB Medical Solutions, a leading medical technology company, is excited to announce that it has been granted funding from Innovation Norway, a government agency supporting innovation and development in various industries. This funding will play a crucial role in propelling MUB Medical’s ongoing work towards prototyping, developing mass production methodologies, and assessing the feasibility of its groundbreaking medical solutions.

The funding received from Innovation Norway serves as a validation of MUB Medical’s innovative approach and underscores the agency’s confidence in the company’s potential to drive advancements in the medical technology sector. With this financial support, MUB Medical will be able to further accelerate its research and development initiatives, bringing them closer to the realization of their transformative medical solutions.

MUB Medical’s focus on prototyping and developing mass production methodologies will enable the company to enhance the scalability and efficiency of its products, making them accessible to a broader audience. By leveraging the funding from Innovation Norway, MUB Medical aims to streamline its manufacturing processes, optimize cost-efficiency, and ensure the highest quality standards for its medical solutions.

Moreover, the feasibility assessment made possible by this funding will provide valuable insights into the practicality and potential impact of MUB Medical’s innovative concepts. This crucial step will help guide the company’s future endeavors, ensuring that their solutions align with market needs and regulatory requirements.

Securing funding from Innovation Norway represents a significant milestone for MUB Medical. It not only provides the financial support necessary for continued progress but also acknowledges the company’s dedication to driving innovation in the medical technology field. The funding reinforces MUB Medical’s commitment to transforming healthcare practices and improving patient outcomes through cutting-edge solutions.

MUB Medical is grateful for the opportunity to collaborate with Innovation Norway and leverage their expertise and resources. This partnership will enable the company to leverage a broad range of support services, networks, and guidance, ultimately accelerating the development and commercialization of their groundbreaking medical solutions.

As MUB Medical moves forward with its prototyping, mass production development, and feasibility assessment, the company remains committed to collaboration, research, and a patient-centered approach. They continue to seek out opportunities for partnerships and industry collaborations to further advance their mission of revolutionizing healthcare through innovative technology.

Explore Patent is Granted in Norway.

Patent Granted in Norway

By Ubbat Ocak in 2021 Posted February 4, 2021

MUB Medical Secures National Patent for Sutrips in Norway, Advancing Global Patenting Strategy

MUB Medical Solutions, a leading medical technology company based in Skien, Norway, is thrilled to announce the successful granting of a national patent for their innovative wound closure device, Sutrips. This milestone marks the completion of the first step in MUB Medical’s comprehensive global patenting strategy for Sutrips.

The granting of the national patent in Norway validates the uniqueness and inventiveness of Sutrips, further solidifying MUB Medical’s position as a pioneer in the field of wound closure. This achievement is a testament to the dedication and expertise of the MUB Medical team, as well as their commitment to driving advancements in healthcare.

Sutrips, an all-in-one device for wound closure, has been meticulously designed with simplicity and effectiveness in mind. It empowers healthcare professionals to securely close wounds with ease, offering a user-friendly solution that enhances patient care and improves treatment outcomes.

Securing the national patent in Norway is a significant milestone for MUB Medical, enabling them to protect their intellectual property rights and pave the way for future commercialization opportunities. This achievement not only reinforces MUB Medical’s commitment to innovation but also positions them as a key player in the global wound closure market.

As part of its broader global patenting strategy, MUB Medical will continue pursuing patent registrations in strategic markets worldwide. By safeguarding their intellectual property, MUB Medical aims to ensure the long-term success and market exclusivity of Sutrips, while advancing their mission to transform wound closure practices and improve patient well-being globally.

The completion of the first step in the global patenting strategy marks an exciting phase for MUB Medical. With their base in Skien, Norway, the company is proud to contribute to the nation’s thriving innovation ecosystem and drive advancements in healthcare technology. This achievement strengthens MUB Medical’s position as a leader in the field and opens doors for further growth and collaboration opportunities.

MUB Medical remains committed to ongoing research, development, and collaboration with healthcare professionals and industry partners. They continue to explore new avenues for advancing wound closure practices and delivering innovative solutions that positively impact patients’ lives.

Explore Norsk Katapult Grant Funding.

Norsk Katapult Grant Funding

By Ubbat Ocak in 2021 Posted January 6, 2021

Funding Foster Collaboration with Norner for Advancement of Sutrips

MUB Medical Solutions, a pioneering medical technology company, is thrilled to announce that it has secured funding from Norsk Katapult, a leading organization supporting innovation and technology development in Norway. This funding will facilitate a close collaboration between MUB Medical and Norner, a renowned industrial polymer Research & Development center with extensive expertise in the polymer and plastics industry.

Norner, boasting over 40 years of experience, stands as a prominent hub for cutting-edge polymer research and development. With a diverse team of 92 employees representing 16 nationalities, Norner is at the forefront of exciting advancements in the field. The collaboration between MUB Medical and Norner represents a significant opportunity to leverage Norner’s wealth of knowledge and resources in the pursuit of furthering the development of Sutrips.

The primary objective of this collaboration is to validate and optimize the design of Sutrips, ensuring its compatibility with medical-grade materials and refining the production methodology. Norner’s deep understanding of polymer science and their proficiency in conducting rigorous testing will be instrumental in assessing the performance, durability, and safety aspects of Sutrips. The ultimate aim is to enhance the functionality and reliability of Sutrips, paving the way for its successful implementation in clinical settings.

The funding provided by Norsk Katapult serves as a testament to MUB Medical’s innovative approach and reinforces the importance of fostering collaborations between industry leaders. This support not only validates the potential of Sutrips but also underscores the significance of advancing medical technology solutions to address critical healthcare challenges.

MUB Medical is excited to embark on this collaborative journey with Norner and is confident that this partnership will yield valuable insights and advancements in the development of Sutrips. By combining Norner’s extensive expertise with MUB Medical’s dedication to innovation and patient-centric design, the collaboration aims to accelerate the progress of Sutrips, ensuring its readiness for market entry.

As the collaboration with Norner unfolds, MUB Medical remains committed to its mission of revolutionizing wound closure and improving patient outcomes. The company believes that by working closely with industry leaders and research institutions, it can foster innovation, drive advancements, and positively impact healthcare practices.

Explore Patent Issued in European Union.

Patent Issued in European Union

By Ubbat Ocak in 2019 Posted December 21, 2019

Patent issued for Sutrips in the European Union –
Validating Uniqueness and Driving Innovation

We are excited to announce that MUB Medical Solutions has successfully secured a patent for our groundbreaking wound closure solution, Sutrips, in the European Union. The approval and issuance of this patent is a significant milestone that validates the uniqueness and exceptional attributes of our innovative product.

The patent grant reinforces our belief in the potential of Sutrips to revolutionize the field of wound closure and motivates us to continue working diligently towards making a positive change on a global scale. It is a testament to the dedication and perseverance of our team, demonstrating that determined efforts yield remarkable results.

“We are thrilled to receive the patent for Sutrips in the European Union,” said Ubbat Ocak, Founder of MUB Medical Solutions. “This achievement underscores the distinctiveness of our solution and affirms our commitment to driving innovation in the field of wound closure. We are inspired to further enhance our product and bring about a positive transformation in healthcare practices worldwide.”

The issuance of the patent in the European Union strengthens our intellectual property rights and provides a solid foundation for our future endeavors. It not only safeguards our innovation but also bolsters our credibility as we seek to collaborate with partners and enter new markets.

“We are proud to have our patent for Sutrips approved and issued in the European Union,” stated Yasar Shaikh, CEO of MUB Medical Solutions. “This milestone fuels our passion to continuously improve and deliver high-quality solutions that address the critical needs of healthcare professionals and patients. It is a testament to the commitment and hard work of our team, and we are excited about the possibilities that lie ahead.”

MUB Medical Solutions remains dedicated to advancing the field of wound closure through relentless innovation, research, and development. With the patent secured, we are inspired to explore new opportunities, forge strategic partnerships, and make a lasting impact on wound closure practices worldwide.

We extend our gratitude to our partners, collaborators, and supporters who have been instrumental in our journey. Together, we will continue to push boundaries, redefine standards, and improve patient outcomes in the realm of wound closure.

Stay connected with MUB Medical Solutions through our website and social media channels for the latest updates on our patented solutions, upcoming collaborations, and our commitment to driving positive change in the field of wound closure.

Explore Trademark Registration in India.

Trademark Registration in India

By Ubbat Ocak in 2019 Posted October 11, 2019

Trademark registration of Sutrips in India

We are excited to share a significant achievement for MUB Medical Solutions. The trademark registration process for our innovative wound closure solution, Sutrips, has been successfully completed in India, a developing market with a cost-conscious population.

The registration of the Sutrips trademark in India strengthens our Intellectual Property rights in this strategically important market. With its vast rural areas and growing healthcare needs, India holds tremendous potential as the largest and most significant market for Sutrips.

“We are delighted to announce the completion of the trademark registration for Sutrips in India,” said Ubbat Ocak, Founder of MUB Medical Solutions. “India presents a significant opportunity for our product, and this registration further establishes our commitment to providing exceptional IP protection for our brand and technologies.”

Recognizing the importance of the Indian market, MUB Medical Solutions is dedicated to delivering the highest level of IP protection to our valued business partners, particularly those who are global key players in the wound closure segment.

“The successful trademark registration in India demonstrates our unwavering commitment to our business partners,” stated Yasar Shaikh, CEO of MUB Medical Solutions. “By securing our intellectual property rights in the Indian market, we enhance our partners’ competitive advantage and solidify our position as leaders in the wound closure industry.”

The completion of the trademark registration for Sutrips in India marks a significant milestone for MUB Medical Solutions. As we continue to cater to the healthcare needs of the Indian population and expand our presence in this crucial market, we remain determined to provide top-notch IP protection and collaborate with global leaders in the wound closure segment.

Stay connected with us through our website and social media platforms to receive the latest updates on our journey. Our commitment to innovation, IP protection, and serving our business partners remains steadfast.

Explore Trade Mark Registration in the USA.

Trademark Registration in USA

By Ubbat Ocak in 2019 Posted July 1, 2019

Trademark Registration of Sutrips in USA

We are thrilled to announce a significant milestone for MUB Medical Solutions. The trademark registration process for our revolutionary wound closure solution, Sutrips, has been successfully completed in the United States, the most critical market for our product.

The successful trademark registration in the USA further strengthens our Intellectual Property rights in this strategically important market. With the American market being the largest and most crucial for Sutrips, this achievement solidifies our position and ensures the protection of our unique brand and cutting-edge technologies.

“We are extremely pleased to have finalized the trademark registration for Sutrips in the United States,” states Ubbat Ocak, Founder of MUB Medical Solutions. “The USA represents a significant market opportunity for our product, and this registration enhances our ability to provide optimal IP protection for our brand and innovations.”

Recognizing the prominence of the United States in the global wound closure segment, MUB Medical Solutions is committed to delivering the highest level of IP protection to our esteemed business partners, particularly those who are key players in the industry.

“The completion of trademark registration in the USA is a major achievement that reinforces our dedication to supporting our global business partners,” emphasizes Yasar Shaikh, CEO of MUB Medical Solutions. “By securing our intellectual property rights in the American market, we ensure a competitive advantage for our partners and reinforce our position as leaders in the wound closure industry.”

The successful registration of the Sutrips trademark in the United States signifies a significant step forward for MUB Medical Solutions. As we continue to expand our presence in key markets, we are determined to provide outstanding IP protection and foster strong collaborations with global leaders in the wound closure segment.

Stay connected with us through our website and social media channels as we embark on this exciting journey. Our commitment to innovation, IP protection, and serving our business partners remains unwavering.

Explore Trademark Registration in China.

Trademark Registration in China

By Ubbat Ocak in 2019 Posted May 5, 2019

Trademark registration of Sutrips in China

MUB Medical Successfully Secures Trademark Registration for Sutrips in China

We are delighted to announce a major accomplishment for MUB Medical Solutions. The trademark registration process for our groundbreaking wound closure solution, Sutrips, has been successfully finalized in the expansive Chinese market.

The completion of trademark registration in China bolsters our commitment to safeguarding our Intellectual Property rights in crucial strategic markets. China’s significance in the healthcare industry makes it an essential market for us, and this registration fortifies our position in protecting the unique brand and cutting-edge technologies of Sutrips.

“Our achievement in securing trademark registration in China is a significant leap forward for MUB Medical Solutions,” expresses Ubbat Ocak, Founder of MUB Medical Solutions. “China offers immense opportunities for Sutrips, and we are resolute in providing the highest level of IP protection to ensure the exclusivity and integrity of our brand.”

As part of our continuous efforts, we are actively pursuing trademark registrations in other identified strategic markets for Sutrips. By establishing a strong global presence, we aim to collaborate with esteemed business partners who are influential leaders in the field of wound closure.

“We are steadfast in delivering exceptional IP protection to our valued business partners, who are instrumental players in the wound closure industry,” emphasizes Yasar Shaikh, CEO of MUB Medical Solutions. “By securing trademark registrations in key markets, we demonstrate our unwavering dedication to safeguarding our innovations and offering a competitive advantage to our partners.”

The successful completion of trademark registration in China signifies a significant milestone that positions MUB Medical Solutions for further growth and success. We will persist in pursuing additional trademark registrations globally, expanding our reach and creating remarkable opportunities for collaboration and market expansion.

Stay connected with us through our website and social media channels as we continue to make remarkable strides in the realm of wound closure. Our unwavering commitment to innovation and providing top-tier IP protection remains at the forefront of our mission to serve our esteemed business partners.

Trademark Registration in UK

By Ubbat Ocak in 2019 Posted April 5, 2019

Trademark Registration in the United Kingdom

We are thrilled to announce that MUB Medical Solutions has achieved a significant milestone in our journey to protect and strengthen our Intellectual Property rights. We have successfully completed the trademark registration process for Sutrips in the United Kingdom, one of our key strategic markets.

This trademark registration is a crucial step towards safeguarding our brand and innovative medical solutions. It provides us with exclusive rights to the Sutrips name and logo, offering enhanced legal protection against unauthorized use or infringement. By securing our intellectual property, we ensure that our partners and customers can trust in the authenticity and quality of our products.

“We are delighted to have completed the trademark registration for Sutrips in the United Kingdom,” says Ubbat Ocak, Founder of MUB Medical Solutions. “This achievement reinforces our commitment to building a strong global presence and protecting our valuable intellectual property. It empowers us to actively prevent counterfeiting and maintain our competitive edge in the market.”

As we continue to expand our reach and serve healthcare professionals worldwide, we recognize the importance of intellectual property protection in key strategic markets. Our team is dedicated to pursuing trademark registration in additional countries that have been identified as vital markets for Sutrips. By proactively securing our IP rights, we create a solid foundation for future growth and ensure that our innovations remain uniquely positioned in the market.

“Our mission is not only to revolutionize wound closure but also to provide our business partners with the highest level of IP protection,” says Yasar Shaikh, CEO of MUB Medical Solutions. “The completion of the trademark registration in the United Kingdom is a significant step towards achieving that goal. We are committed to delivering the best possible IP protection for our partners and customers, enabling them to confidently collaborate with us and leverage the benefits of our innovative solutions.”

MUB Medical Solutions is proud to have achieved this milestone in our intellectual property journey. We remain steadfast in our dedication to delivering cutting-edge medical devices and ensuring that our partners and customers receive the utmost protection and value from their association with us.

Stay tuned as we continue to make strides in advancing wound closure technology and expanding our IP protection worldwide. Follow us on our social media platforms and website to stay informed about our latest updates and exciting developments.

Explore EU Design Registration.

EU Design Registration

By Ubbat Ocak in 2019 Posted February 4, 2019

Design Registration of Sutrips in the EU

MUB Medical is thrilled to announce that the design of Sutrips has been successfully granted protection in the European Union (EU). This design protection further bolsters our strong intellectual property (IP) rights surrounding Sutrips, which is already patented in the EU.

The design protection for Sutrips in the EU is a significant achievement for our company. It ensures that the unique and innovative design of Sutrips is legally safeguarded, providing us with exclusive rights to its visual appearance. This protection reinforces our commitment to delivering cutting-edge medical solutions while safeguarding our intellectual assets.

With Sutrips, we bring numerous advantages to the field of wound closure. Sutrips is a revolutionary all-in-one suture tool that simplifies the wound closure process. Its ergonomic design and user-friendly features enable medical professionals to efficiently and effectively close wounds. By combining all the necessary components of a traditional stitching kit into a single device, Sutrips streamlines procedures, saves time, and enhances patient care.

In addition to its design and functionality, Sutrips offers exceptional versatility. It is suitable for various wound types, sizes, and locations, making it a valuable tool for emergency rooms, surgical procedures, and everyday wound care. With Sutrips, healthcare professionals can achieve precise wound closure, leading to improved outcomes and patient satisfaction.

The combination of patent protection and design protection in the EU for Sutrips strengthens our position as a leader in the field of wound closure innovation. We remain committed to advancing medical solutions that make a meaningful difference in healthcare, and we are proud to have Sutrips at the forefront of this mission.

For more information about Sutrips and our innovative products, please visit our website or contact our team. Together, we can revolutionize wound closure and improve patient care worldwide.

Explore Geneticum and Proventia.

Geneticum and Proventia

By Ubbat Ocak in 2019 Posted January 5, 2019

MUB Medical Granted Funding & Joins Proventia Incubator Program to Drive Growth and Innovation!

We are delighted to announce that MUB Medical Solutions has successfully secured funding from two esteemed organizations, Stiftelsen Geneticum and Proventia. This financial support marks a significant milestone in our journey to bring Sutrips to the forefront of the wound closure industry.

The funding received from Stiftelsen Geneticum and Proventia will play a vital role in our mission to advance the regulatory pathway for Sutrips. With this financial backing, we will initiate a comprehensive study to navigate the regulatory landscape and ensure compliance with industry standards and requirements. This important step brings us closer to achieving the necessary certifications and approvals needed to bring Sutrips to market.

“We are incredibly grateful for the generous funding provided by Stiftelsen Geneticum and Proventia,” says Ubbat Ocak, Founder of MUB Medical Solutions. “Their support is a testament to their belief in our vision and the potential impact of Sutrips in revolutionizing wound closure. With this funding, we can accelerate our efforts to navigate the regulatory pathway and ensure that Sutrips meets all necessary regulatory standards.”

By securing these funds, we can dedicate resources to conduct in-depth research, collaborate with regulatory experts, and streamline the process of obtaining regulatory approvals. This study will provide us with valuable insights and enable us to develop a robust regulatory strategy that ensures the safety, efficacy, and compliance of Sutrips.

Yasar Shaikh, CEO of MUB Medical Solutions, emphasizes the significance of this funding in propelling our mission forward. “The funding from Stiftelsen Geneticum and Proventia is a game-changer for us. It enables us to take concrete steps towards fulfilling regulatory requirements and ultimately bringing Sutrips to the hands of healthcare professionals and patients who can benefit from its innovative wound closure capabilities.”

We extend our deepest gratitude to Stiftelsen Geneticum and Proventia for their trust and support in our vision. Their funding enables us to forge ahead in our mission to improve wound closure practices and provide healthcare professionals with a revolutionary solution.

Stay tuned for more updates as we progress through the regulatory pathway and work towards making Sutrips a reality. Follow us on our social media platforms and website to stay informed about our latest developments and milestones.

Explore Klosteroya Fondet and Proventia.